Does Medicare cover weight loss medications? How access to GLP-1s is changing

GLP-1 medications have become a permanent part of weight loss conversations as more people are using them to improve their health. But part of the conversation always includes price, since these drugs are typically priced at over $1,000 a month. And since insurance coverage has historically been rare, it’s important to know the current rules and regulations around coverage and where things stand now.

This is particularly important for people covered by Medicare. Medicare provides health coverage for millions of Americans, mostly people over 65. Since prescription costs can add up fast for this group, having coverage can make a huge difference. So, where do weight loss drugs fit into Medicare today?

Here’s the short version: Medicare historically hasn’t covered GLP-1 medications when they’re prescribed solely for weight loss, as a standard, permanent benefit. That’s been federal policy for about two decades. But as of July 1, 2026, a temporary program called the Medicare GLP-1 Bridge is letting eligible beneficiaries access select weight-loss GLP-1s for a flat $50 a month. 

This program represents the first time Medicare has helped pay for a medication used specifically for weight loss. Below, we cover what’s covered today, how the new Bridge program works, and how Noom’s Medicare Bridge program can help you use it.

Does Medicare cover weight loss drugs?

Yes—as of July 1, 2026, eligible beneficiaries can get select GLP-1s for weight loss through the Medicare GLP-1 Bridge program, a temporary CMS program covered in detail below, for a $50 copay per fill. 

Outside the Bridge program, standard Medicare drug coverage (Part D and Medicare Advantage) still excludes medications prescribed for weight loss alone. To access the Bridge, you need to be enrolled in an eligible Part D or Medicare Advantage plan.

Why hasn’t Medicare’s standard drug benefit covered weight loss medications?

When Medicare Part D was created in the mid-2000s, the law excluded drugs used for weight management purposes, a rule that traces back to safety concerns about weight loss drugs in the 1990s. That exclusion still applies to standard coverage today, even as obesity is now widely treated as a chronic medical condition. The GLP-1 Bridge program doesn’t repeal that exclusion; it’s a separate, temporary program running alongside it.

The Medicare GLP-1 Bridge Program: What changed in 2026

Medicare drug pricing and access have shifted on two fronts:

First, the Centers for Medicare & Medicaid Services (CMS) negotiated lower prices for a set of high-cost medications through the drug price negotiation program created under the Inflation Reduction Act. Those negotiated prices, which include some GLP-1 medications used for FDA-approved conditions like diabetes, are set to take effect for Part D drugs in 2027.

Second—and more directly relevant to weight loss coverage—CMS launched the Medicare GLP-1 Bridge program on July 1, 2026. This is a short-term demonstration program, not a permanent change to the law, that gives eligible Medicare Part D beneficiaries access to certain GLP-1 drugs for weight management at a flat $50 monthly copay. Participating manufacturers supply the medications to the program at a reduced net price of about $245 per monthly fill, which is what makes the $50 copay possible.

The Bridge program currently covers three brand-name GLP-1s: 

• Wegovy® (injection and tablets)
• Zepbound® KwikPen® (not the single-dose pen or vial formulations)
• Foundayo® (orforglipron)

 It’s available nationwide, and the $50 copay is the same regardless of dose.

The Bridge program runs outside your normal Part D benefit—a single central processor (Humana, via its Limited Income Newly Eligible Transition infrastructure) handles prior authorization, claims, and pharmacy payment, so your Part D plan doesn’t administer or pay for it. That also means the $50 copay doesn’t count toward your Part D deductible or your annual out-of-pocket cap.

Who qualifies for Medicare GLP-1 Bridge?

To be eligible, you need to be enrolled in an eligible Part D or Medicare Advantage prescription drug plan and meet a BMI threshold. 

A BMI of 35 or higher on its own, or a lower BMI (30+ or 27+) combined with a qualifying condition such as hypertension, heart disease, kidney disease, or pre-diabetes. 

Importantly, eligibility is based on your BMI and health history at the time you started GLP-1 therapy, not necessarily where you stand today. That means weight you’ve already lost on a GLP-1 won’t disqualify you. Your provider handles the documentation and prior authorization request.

What will disqualify you is having certain conditions—type 2 diabetes, moderate to severe obstructive sleep apnea, or MASH. In those cases, you won’t qualify for the Bridge program because your GLP-1 would instead be covered under standard Part D coverage.

The Medicare GLP-1 Bridge is currently scheduled to run through December 31, 2027.

How Noom can help you use the Medicare GLP-1 Bridge

Because the Medicare GLP-1 Bridge runs through its own prior-authorization process rather than a standard prescription, getting access can mean extra paperwork. Your provider must determine eligibility, submit the request, and track it down at a participating pharmacy. Noom’s Medicare Bridge program is built to handle that on your behalf if you qualify:

• Noom handles the prescribing and paperwork. A Noom clinician evaluates your eligibility and, if appropriate, prescribes a covered medication and submits the prior authorization and insurance paperwork required by the Bridge.
• Free shipping from Noom’s partner pharmacy, with medication sent directly to your door.
• You’ll pay $50 per fill if you’re eligible, billed through your Medicare Bridge benefit, applying every time your prescription is filled, at any dose.

There are two separate costs not covered by Medicare to factor in beyond the medication itself:

• $39 to get started: Covers your first evaluation with a Noom clinician, done entirely online.
• $99 a month: For your Noom Med plan, which covers your care team, ongoing clinical support, and all the benefits of Noom, including habit-building tools, a vibrant community, recipes, on-demand exercises, and more. (Billed as $297 every 12 weeks) 

See if you’re eligible for Noom Medicare Bridge.

Weight loss drugs and Medicare: GLP-1 coverage depends on the pathway

Outside of the Bridge, Medicare may still cover certain GLP-1 medications through standard Part D—but only when they’re prescribed for another FDA-approved condition, not weight loss alone:

• Type 2 diabetes (blood sugar management): Ozempic® (semaglutide), Mounjaro® (tirzepatide), Rybelsus® (semaglutide), Trulicity® (dulaglutide), and Victoza® (liraglutide).
• Cardiovascular risk reduction: Wegovy® (semaglutide) and Victoza® (liraglutide).
• Obstructive sleep apnea (OSA): Zepbound® (tirzepatide).

Whether a specific prescription is covered depends on a few factors: what the medication is officially approved to treat, how your provider documents the diagnosis, your plan’s formulary, and any utilization management rules like prior authorization or step therapy.

Medication (brand name)	FDA approval(s)	Standard Part D coverage?	Bridge-eligible for weight loss?
Ozempic® (semaglutide)	Type 2 diabetes	May be covered for diabetes	No
Wegovy® (semaglutide)	Weight management, heart disease, MASH	May be covered for heart disease or MASH	Yes
Rybelsus® (semaglutide)	Type 2 diabetes	May be covered for diabetes	No
Mounjaro® (tirzepatide)	Type 2 diabetes	May be covered for diabetes	No
Zepbound® (tirzepatide)	Weight management; obstructive sleep apnea	May be covered for OSA	Yes (KwikPen® only)
Foundayo® (orforglipron)	Weight management	Not covered outside the Bridge	Yes
Victoza® (liraglutide)	Type 2 diabetes, heart disease	May be covered for diabetes or heart disease	No
Saxenda® (liraglutide)	Weight management	Not covered	No
Trulicity® (dulaglutide)	Type 2 diabetes	May be covered for diabetes	No

Coverage details can change; confirm current status with your plan or provider.

Medicare and weight loss drugs: Part D vs. Medicare Advantage

A common misconception is that Medicare Advantage plans cover more than Part D, so weight-loss drugs might be included there. Here’s the clearer split:

• Medicare Part D is strictly prescription coverage, enrolled in alongside Original Medicare, and it follows Medicare’s federal rules on what drug categories can and can’t be covered.
• Medicare Advantage (Part C) is a full replacement plan that takes the place of Original Medicare and usually includes drug coverage plus extra benefits Part D doesn’t offer, such as gym memberships, wellness programs, or health coaching.

Both still follow the same federal prescription drug rules, so neither can cover weight-loss drugs by law through standard coverage. The Medicare GLP-1 Bridge sits outside both of these—it’s available to people enrolled in eligible standalone Part D plans or Medicare Advantage plans with drug coverage, but it’s processed separately from either plan type.

Will Medicare permanently cover weight loss drugs?

Full, permanent Medicare coverage of weight-loss drugs would require new legislation or a permanent policy change—something Congress hasn’t done. The Medicare GLP-1 Bridge program is a demonstration project, run under CMS’s authority to test payment models, not a change to the underlying law. CMS has said the data collected during the Bridge program will help inform whether a broader, longer-term program follows.

The next step that had been planned—the BALANCE Model (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth)—was meant to take over from the Bridge in January 2027 with a broader structure involving both Medicaid and Part D plan sponsors. That transition didn’t happen on schedule because not enough insurers opted in, so CMS extended the Bridge itself through December 31, 2027 instead. Whether BALANCE, a further extension of the Bridge, or something else follows after that is not yet determined.

Does Medicare cover weight loss drugs for seniors specifically?

Medicare’s rules are the same for everyone enrolled in the program, regardless of age—coverage doesn’t change based on being a senior versus another category of beneficiary. This question comes up often because many older adults are managing conditions like type 2 diabetes or heart disease, where GLP-1 coverage is more likely to apply, and because prescription costs can be a major expense on a fixed income. Whether coverage applies still comes down to diagnosis, documentation, your plan’s formulary, and now, for weight loss specifically, Bridge eligibility.

What are your options if Medicare doesn’t cover your GLP-1?

If you don’t qualify for the Bridge, or you’re prescribed a medication it doesn’t cover, there are still a few practical paths:

Check Bridge first. Since it doesn’t require a new insurance plan—only enrollment in an eligible Part D or Medicare Advantage plan—it’s worth confirming with your provider whether you meet the BMI and health-history criteria before assuming you need to pay full price. Noom’s Medicare Bridge program can help evaluate eligibility and handle the paperwork.

Pay cash through manufacturer direct-pay programs. People enrolled in Medicare can pay cash for a medication instead of using insurance, filling prescriptions through programs like NovoCare® Pharmacy or LillyDirect® at their listed prices. Keep in mind that cash payments won’t count toward your Medicare deductible or out-of-pocket maximum, and not all providers route prescriptions through direct-pay pharmacies.

Medication	List price/month	Direct-pay alternative/month
Wegovy® (semaglutide)	$1,349	NovoCare® Pharmacy:  $199-$349 injection $149–$299 pill
Zepbound® (tirzepatide)	$1,087	LillyDirect®: $299-$449 (KwikPen and vial)
Foundayo® (orforglipron)	$649	LillyDirect®: $149–$299

Prices vary by pharmacy and are subject to change.

Frequently asked questions about Medicare and weight loss drugs

Why doesn’t Medicare cover weight loss drugs as a standard benefit? 

Federal law has excluded drugs prescribed for weight loss from standard Medicare Part D coverage since the program was created in the mid-2000s, following safety concerns about weight-loss drugs in the 1990s. That exclusion is still the underlying law—the Medicare GLP-1 Bridge is a temporary demonstration program that works around it, not a repeal of it.

What is Medicare GLP-1 Bridge? 

It’s a short-term CMS demonstration, currently planned to run July 1, 2026 through December 31, 2027, that gives eligible Medicare Part D beneficiaries access to Wegovy®, Zepbound® KwikPen®, and Foundayo® for weight management at a $50 monthly copay, regardless of dose.

Does Medicare pay for any other weight loss treatments? 

People with a BMI of 30 or higher may be eligible for intensive behavioral therapy through Medicare Part B, covering counseling on nutrition, physical activity, and behavior change. For bariatric surgery, Medicare typically requires a BMI of 35 or higher plus at least one obesity-related condition, along with documentation that non-surgical approaches were tried without sufficient success.

Does Medicare cover GLP-1 medications for diabetes? 

Yes. Medicare may cover medications like Ozempic® or Mounjaro® under Part D when they’re prescribed for type 2 diabetes, though most plans require prior authorization and some use step therapy. Coverage still depends on your specific plan’s formulary.

Can Medicare Advantage plans cover weight loss drugs? 

Medicare Advantage plans follow the same federal drug coverage rules as Part D, so they can’t cover medications prescribed only for weight loss, outside of the Bridge program. Coverage may still apply when a GLP-1 is prescribed for diabetes, heart disease, or OSA.

The bottom line: Medicare’s GLP-1 Bridge program can help some beneficiaries get GLP-1 medications for $50 per month 

Standard Medicare still doesn’t cover GLP-1 medications prescribed for weight loss alone—that underlying rule hasn’t changed. What has changed is the temporary Medicare GLP-1 Bridge, which since July 2026 gives eligible beneficiaries access to Wegovy®, Zepbound® KwikPen®, and Foundayo® for $50 a month through the end of 2027. 

Whether that access becomes permanent, gets replaced by a program like BALANCE, or ends when the Bridge expires is still unresolved. In the meantime, checking your eligibility for Bridge—including through a program like Noom’s Medicare Bridge—is the most direct way to find out what you’ll actually pay.

---

This article is for general education and isn’t medical or insurance advice. Medicare rules, drug approvals, and prices change often—confirm current details with CMS, Medicare.gov, your plan, and your healthcare provider before making decisions.